| Characteristics . | 1994–2000 . | 2001–2007 . | 2008–2013 . | 2014–2019 . | P-value . |
|---|---|---|---|---|---|
| Kidney biopsies (n) | 7896 | 7052 | 6396 | 7447 | |
| Lupus nephritis, n (%) | 728 (9.2) | 707 (10) | 624 (9.8) | 521 (7.0) | <0.001 |
| Age (years), mean ± SD | 32.1 ± 13.6 | 35.3 ± 13.9 | 35.8 ± 12.7 | 37.8 ± 13.8 | <0.001 |
| Female:male ratio | 4.2:1 | 4.5:1 | 4.5:1 | 4:1 | 0.809 |
| Hypertension, n (%) | 261 (35.9) | 277 (39.2) | 242 (38.8) | 208 (39.9) | 0.437 |
| Serum creatinine (mg/dL), median (IQR) | 1 (0.8–1.5) | 1 (0.8–1.4) | 0.9 (0.7–1.3) | 0.9 (0.7–1.2) | <0.001 |
| eGFR (mL/min/1.73 m2)a, mean ± SD | 74.4 ± 34.5 | 78.7 ± 35.4 | 78.8 ± 36.5 | 80.5 ± 36.7 | 0.056 |
| Proteinuria (g/day), median (IQR) | 3 (1.7–5.2) | 3 (1.5–5) | 2 (1–4) | 2 (1–4.1) | <0.001 |
| eGFR <60 mL/min/1.73 m2, n (%) | 158 (32.8) | 160 (30.2) | 161 (30.7) | 151 (29.9) | 0.752 |
| Kidney biopsy indication, n (%) | |||||
| Non-nephrotic proteinuria | 283 (41.3) | 229 (33.3) | 273 (44.1) | 241 (46.3) | 0.001 |
| Nephrotic syndrome | 292 (42.6) | 299 (43.5) | 212 (34.2) | 159 (30.5) | <0.001 |
| Nephritic syndrome | 43 (6.3) | 67 (9.7) | 62 (10) | 66 (12.7) | <0.001 |
| CKD | 24 (3.5) | 35 (5.1) | 30 (4.8) | 19 (3.6) | 0.3 |
| AKI | 35 (5.1) | 50 (7.3) | 33 (5.3) | 34 (6.5) | 0.25 |
| Others | 51 (7) | 27 (3.8) | 14 (2.2) | 2 (0.4) | 0.001 |
| Characteristics . | 1994–2000 . | 2001–2007 . | 2008–2013 . | 2014–2019 . | P-value . |
|---|---|---|---|---|---|
| Kidney biopsies (n) | 7896 | 7052 | 6396 | 7447 | |
| Lupus nephritis, n (%) | 728 (9.2) | 707 (10) | 624 (9.8) | 521 (7.0) | <0.001 |
| Age (years), mean ± SD | 32.1 ± 13.6 | 35.3 ± 13.9 | 35.8 ± 12.7 | 37.8 ± 13.8 | <0.001 |
| Female:male ratio | 4.2:1 | 4.5:1 | 4.5:1 | 4:1 | 0.809 |
| Hypertension, n (%) | 261 (35.9) | 277 (39.2) | 242 (38.8) | 208 (39.9) | 0.437 |
| Serum creatinine (mg/dL), median (IQR) | 1 (0.8–1.5) | 1 (0.8–1.4) | 0.9 (0.7–1.3) | 0.9 (0.7–1.2) | <0.001 |
| eGFR (mL/min/1.73 m2)a, mean ± SD | 74.4 ± 34.5 | 78.7 ± 35.4 | 78.8 ± 36.5 | 80.5 ± 36.7 | 0.056 |
| Proteinuria (g/day), median (IQR) | 3 (1.7–5.2) | 3 (1.5–5) | 2 (1–4) | 2 (1–4.1) | <0.001 |
| eGFR <60 mL/min/1.73 m2, n (%) | 158 (32.8) | 160 (30.2) | 161 (30.7) | 151 (29.9) | 0.752 |
| Kidney biopsy indication, n (%) | |||||
| Non-nephrotic proteinuria | 283 (41.3) | 229 (33.3) | 273 (44.1) | 241 (46.3) | 0.001 |
| Nephrotic syndrome | 292 (42.6) | 299 (43.5) | 212 (34.2) | 159 (30.5) | <0.001 |
| Nephritic syndrome | 43 (6.3) | 67 (9.7) | 62 (10) | 66 (12.7) | <0.001 |
| CKD | 24 (3.5) | 35 (5.1) | 30 (4.8) | 19 (3.6) | 0.3 |
| AKI | 35 (5.1) | 50 (7.3) | 33 (5.3) | 34 (6.5) | 0.25 |
| Others | 51 (7) | 27 (3.8) | 14 (2.2) | 2 (0.4) | 0.001 |
aCalculated by the Chronic Kidney Disease Epidemiology Collaboration equation.
| Characteristics . | 1994–2000 . | 2001–2007 . | 2008–2013 . | 2014–2019 . | P-value . |
|---|---|---|---|---|---|
| Kidney biopsies (n) | 7896 | 7052 | 6396 | 7447 | |
| Lupus nephritis, n (%) | 728 (9.2) | 707 (10) | 624 (9.8) | 521 (7.0) | <0.001 |
| Age (years), mean ± SD | 32.1 ± 13.6 | 35.3 ± 13.9 | 35.8 ± 12.7 | 37.8 ± 13.8 | <0.001 |
| Female:male ratio | 4.2:1 | 4.5:1 | 4.5:1 | 4:1 | 0.809 |
| Hypertension, n (%) | 261 (35.9) | 277 (39.2) | 242 (38.8) | 208 (39.9) | 0.437 |
| Serum creatinine (mg/dL), median (IQR) | 1 (0.8–1.5) | 1 (0.8–1.4) | 0.9 (0.7–1.3) | 0.9 (0.7–1.2) | <0.001 |
| eGFR (mL/min/1.73 m2)a, mean ± SD | 74.4 ± 34.5 | 78.7 ± 35.4 | 78.8 ± 36.5 | 80.5 ± 36.7 | 0.056 |
| Proteinuria (g/day), median (IQR) | 3 (1.7–5.2) | 3 (1.5–5) | 2 (1–4) | 2 (1–4.1) | <0.001 |
| eGFR <60 mL/min/1.73 m2, n (%) | 158 (32.8) | 160 (30.2) | 161 (30.7) | 151 (29.9) | 0.752 |
| Kidney biopsy indication, n (%) | |||||
| Non-nephrotic proteinuria | 283 (41.3) | 229 (33.3) | 273 (44.1) | 241 (46.3) | 0.001 |
| Nephrotic syndrome | 292 (42.6) | 299 (43.5) | 212 (34.2) | 159 (30.5) | <0.001 |
| Nephritic syndrome | 43 (6.3) | 67 (9.7) | 62 (10) | 66 (12.7) | <0.001 |
| CKD | 24 (3.5) | 35 (5.1) | 30 (4.8) | 19 (3.6) | 0.3 |
| AKI | 35 (5.1) | 50 (7.3) | 33 (5.3) | 34 (6.5) | 0.25 |
| Others | 51 (7) | 27 (3.8) | 14 (2.2) | 2 (0.4) | 0.001 |
| Characteristics . | 1994–2000 . | 2001–2007 . | 2008–2013 . | 2014–2019 . | P-value . |
|---|---|---|---|---|---|
| Kidney biopsies (n) | 7896 | 7052 | 6396 | 7447 | |
| Lupus nephritis, n (%) | 728 (9.2) | 707 (10) | 624 (9.8) | 521 (7.0) | <0.001 |
| Age (years), mean ± SD | 32.1 ± 13.6 | 35.3 ± 13.9 | 35.8 ± 12.7 | 37.8 ± 13.8 | <0.001 |
| Female:male ratio | 4.2:1 | 4.5:1 | 4.5:1 | 4:1 | 0.809 |
| Hypertension, n (%) | 261 (35.9) | 277 (39.2) | 242 (38.8) | 208 (39.9) | 0.437 |
| Serum creatinine (mg/dL), median (IQR) | 1 (0.8–1.5) | 1 (0.8–1.4) | 0.9 (0.7–1.3) | 0.9 (0.7–1.2) | <0.001 |
| eGFR (mL/min/1.73 m2)a, mean ± SD | 74.4 ± 34.5 | 78.7 ± 35.4 | 78.8 ± 36.5 | 80.5 ± 36.7 | 0.056 |
| Proteinuria (g/day), median (IQR) | 3 (1.7–5.2) | 3 (1.5–5) | 2 (1–4) | 2 (1–4.1) | <0.001 |
| eGFR <60 mL/min/1.73 m2, n (%) | 158 (32.8) | 160 (30.2) | 161 (30.7) | 151 (29.9) | 0.752 |
| Kidney biopsy indication, n (%) | |||||
| Non-nephrotic proteinuria | 283 (41.3) | 229 (33.3) | 273 (44.1) | 241 (46.3) | 0.001 |
| Nephrotic syndrome | 292 (42.6) | 299 (43.5) | 212 (34.2) | 159 (30.5) | <0.001 |
| Nephritic syndrome | 43 (6.3) | 67 (9.7) | 62 (10) | 66 (12.7) | <0.001 |
| CKD | 24 (3.5) | 35 (5.1) | 30 (4.8) | 19 (3.6) | 0.3 |
| AKI | 35 (5.1) | 50 (7.3) | 33 (5.3) | 34 (6.5) | 0.25 |
| Others | 51 (7) | 27 (3.8) | 14 (2.2) | 2 (0.4) | 0.001 |
aCalculated by the Chronic Kidney Disease Epidemiology Collaboration equation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
